HK Stock MarketDetailed Quotes

02181 MABPHARM-B

Watchlist
  • 0.495
  • 0.0000.00%
Market Closed Mar 28 16:08 CST
2.04BMarket Cap-8839P/E (TTM)

About MABPHARM-B Company

We are a leading biomedical company in China, focusing on the development and industrialization of new drugs and biosimilar drugs to treat cancer and autoimmune diseases. We are committed to bringing high-quality and affordable innovative biopharmaceuticals to the market through an efficient R&D system and low-cost drug production capacity, and making full use of our rich R&D experience to develop a variety of therapeutic products. Our drug pipeline currently includes 10 monoclonal antibody drugs and 1 strong antibody drug, 3 of which are our core products: CMAB008 (infliximab): It was approved for marketing by China Drug Administration (“China Drug Administration”) in July 2021 (Sinopharm Standard S20210025), and approved for the treatment of the following indications: 1) ulcerative colitis in adults; 2) ankylosing spondylitis; 3) rheumatoid arthritis; 4) Crohn's disease in adults and children aged 6 and above; 5) tubular Crohn's disease; 6) psoriasis. Taizhou Maibotech Pharmaceutical Co., Ltd., a subsidiary of our company, has also successfully passed the GMP compliance inspection of CMAB008 by the Jiangsu Drug Administration at China Pharmaceutical City in Taizhou, Jiangsu. CMAB008 is also automatically included in medical insurance in accordance with China's basic medical insurance (“health insurance”) regulations, and has obtained a drug health insurance code registered by the China National Health Insurance Administration (“Health Insurance Administration”). CMAB008 has been discontinued for the treatment of six indications. The number of patients with these indications in China has exceeded 10 million and continues to grow, and there is huge market demand that has not been met for a long time. We have completed the procurement network of 30 provincial platforms in China and the inclusion of provincial health insurance systems, and completed channel layout and delivery in 30 provinces. During the reporting period, Taizhou Maibotech Pharmaceutical Co., Ltd. (“Taizhou Pharmaceutical”), an indirect wholly-owned subsidiary of the Company, entered into an exclusive promotion service agreement with Kexing Biopharmaceuticals Co., Ltd. (“Kexing Biopharmaceuticals”) (a company listed on the Shanghai Stock Exchange Science and Technology Innovation Board (stock code: 688136)). Based on this, Taizhou Pharmaceutical has granted Kexing Biopharmaceuticals an exclusive promotion license to stop CMAB008 in mainland China (excluding Hong Kong, Macau and Taiwan, China). Taizhou Pharmaceutical will collect commercial milestones and milestones for this exclusive promotion license item, It is also expected to generate considerable revenue from continuous sales in the future. For details of the above transactions, please refer to the Company's announcement dated March 31, 2022. Based on high-quality innovative drugs, Maibo Pharmaceutical will provide affordable innovative antibody drug supply to the vast majority of Chinese patients with more economical drug delivery plans and initiatives to fully participate in China's national medical system reform; the company has also initiated cooperation with partners that have long accumulated rich overseas market resources to rapidly expand overseas markets. Currently, registration and expansion work has begun in more than 30 countries and/or regions. CMAB007 (omalizumab): Clinical trials and new drug application data compilation for phase III asthma indications have been completed. CMAB007's new drug marketing application was submitted to the State Drug Administration in October 2021, and on-site inspection by the State Drug Administration has been successfully completed. It is expected to be approved for marketing in the first quarter of 2023. It is expected that this drug will be the first domestically produced omazumab drug marketed in China after marketing. The company is seeking CMAB007 cooperation from leading Chinese pharmaceutical sales companies to achieve rapid growth in CMAB007 sales. Since similar drugs have been approved overseas for urticaria and allergic rhinitis indications, and are being developed to address food allergy indications, we will speed up the clinical and registration work of CMAB007 for such indications in order to grasp the huge market demand for allergic diseases in China. CMAB009 (cetuximab): A phase III clinical trial for colorectal cancer is being carried out. All cases have been enrolled, and NDA data compilation, analysis, and statistics will soon be completed. CMAB009 was developed using a Chinese hamster ovary cell (“CHO”) expression system, and has significant safety advantages over cetuximab drugs currently marketed to treat metastatic colorectal cancer. CMAB009 is expected to submit a new drug marketing application to the State Drug Administration in the fourth quarter of 2022. CMAB807 (desulumab): A phase III clinical trial for osteoporosis is being carried out. Case enrollment has been completed, and the NDA application data compilation stage has been completed. The clinical trial application (CMAB807X) for treating tumor bone metastases was approved by the State Drug Administration in January 2022 (Drug Clinical Trial Approval Notice No.: 2022LP00032). Among our other drug candidates, the new “strong antibody” drug CMAB017 has been approved by the National Drug Administration for the treatment of advanced solid tumors, including but not limited to clinical trials of colorectal cancer, head and neck squamous cell carcinoma, and esophageal squamous cell carcinoma. Compared with EGFR antibody drugs currently on the market, CMAB017 has good efficacy and safety. Additionally, we have begun phase I clinical trials of CMAB819 (navulimab). The biosimilar CMAB015 (scuchiumab) developed by us has been approved and clinical trials are being initiated. The drug has significant curative advantages in autoimmune diseases such as psoriasis, and has become one of the most rapidly growing biologics in the field of psoriasis in China. We have also developed the biosimilar CMAB022 (usinumab), which has good market prospects in the fields of psoriasis, ankylosing spondylitis and Crohn's disease. We have strong in-house pharmaceutical research, production, and pre-clinical and clinical development capabilities. We plan to promote the industrialization of the company's drug development through sales license cooperation and the establishment of our own sales team. On the one hand, we will make full use of our partners' strong sales resources and experience over the years, and on the other hand, build and improve our own unique efficient sales system from specific fields of indication. We focus on the development of monoclonal antibodies. Our core R&D team members have more than 19 years of experience in this field and have presided over national scientific research projects including 3 major “863” projects. Additionally, one of our core R&D team members is a member of the 11th National Pharmacopeia Committee. We completed the construction of three new production lines in Taizhou in 2021, increasing the total volume of our cellular reactors to 18,000 liters. We have also completed the construction of a plant at our new R&D industrial base in Taizhou. The large-scale GMP production line under construction by our company has already entered the installation and commissioning stage. It is expected to be put into use by the end of 2022. At that time, the total scale of our cellular reactors will exceed 40,000 liters. We have a solid foundation of equipment, technology and quality in the field of antibody drug preparation, which will give us an excellent competitive advantage in future medical insurance procurement negotiations. Relying on our superior domestic antibody drug development and industrialization capabilities, we are also actively expanding and implementing the CDMO business without affecting our own product development, and have achieved satisfactory performance results. We believe we will be able to seize China's huge market opportunities, particularly those brought about by China's recent health-care regulatory reforms (including new health insurance measures). Our main focus of research and development is monoclonal antibody drugs for cancer and autoimmune diseases. These drugs have huge undeveloped clinical demand in China. Furthermore, with the rapid development of the Chinese pharmaceutical market, medical insurance collection that may cover biopharmaceuticals in the future and the strengthening of national health insurance negotiations will largely restructure the Chinese pharmaceutical market. We will use our advantages in advanced technology, quality and cost, and an active and flexible product cooperation model to actively participate in national health care reform, seize the opportunities brought by policy reforms, and seize the huge unmet market demand in China. We have initiated global market development and accelerated the registration and marketing of our medicines in international markets.

Company Profile

Symbol02181
Company NameMABPHARM-B
ISINKYG5780F1046
Listing Date05/31/2019
Issue Price1.50
Shares Offered783.58M share
Founded06/01/2018
RegistrationCayman Islands
ChairmanShuge Jiao
SecretaryHaoxian\liyunfeng Ceng
Audit InstitutionErnst & Young
Company CategoryOverseas registration of Mainland Individuals control
Registered Office190 Elgin Avenue George Town Grand Cayman KY1-9008 Cayman Islands
Head Office and Principal Place of BusinessRoom A, 18th floor, Hung Cheung Centre, 83 Queen's Road East, Wan Chai, Hong Kong
Fiscal Year Ends12-31
Employees347
MarketHong Kong motherboard
Phone(852)31506788
Fax(852)31506728
Emailmabpharm.hk@pordahavas.com
Business Maibo Pharmaceutical Co., Ltd. is a Chinese company mainly engaged in research, development and production of monoclonal antibody drugs for cancer and autoimmune diseases. The company's main products include omalizumab (CMAB007), cetuximab (CMAB009), and infliximab (CMAB008). The company mainly operates within China.

Company Executives

  • Name
  • Position
  • Salary
  • Hao Wang
  • Executive Director,CEO,Chief Scientist,Remuneration Committee Member
  • --
  • Yunfeng Li
  • CFO,Executive Director,Authorized Representative,Joint Company Secretary
  • --
  • Jing Li
  • VP
  • --
  • Sheng Hou
  • Executive Director
  • --
  • Jing Tao
  • Nomination Committee Member,VP,Executive Director,General Manager of Taizhou Pharmaceutical
  • --
  • Weizhu Qian
  • Non-Executive Director
  • --
  • Shuge Jiao
  • Non-Executive Director,Chairman,Audit Committee Member
  • --
  • Liangzhong Guo
  • Remuneration Committee Member,Audit Committee Member,Independent Non-Executive Director,Nomination Committee Chairman
  • --
  • Yanyun Zhang
  • Independent Non-Executive Director,Nomination Committee Member,Remuneration Committee Chairman
  • --
  • Haoming Liang
  • Audit Committee Chairman,Independent Non-Executive Director
  • --
  • Wenhui Zhuge
  • Corporate Advisor
  • --
  • Haoxian Ceng
  • Joint Company Secretary,Authorized Representative
  • --

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
HK
Overall
Symbol
Latest Price
%Chg